Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects

British Journal of Clinical Pharmacology

Volumn 53, Issue 4, 2002, Pages 355-362

  Dingemanse, Jasper ^a   Clozel, Martine ^a   Van Giersbergen, Paul L M ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Endothelin antagonist; Endothelin 1; Infusion; Pharmacodynamics; Pharmacokinetics; Tezosentan

Indexed keywords

DRUG METABOLITE; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO; RO 64 1538; TEZOSENTAN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE HEART FAILURE; ADULT; ARTICLE; BACKACHE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INFUSION; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FLUSHING; HEADACHE; HEART PALPITATION; HEMATOMA; HUMAN; INCIDENCE; MALE; MEASUREMENT; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECORDING; STEADY STATE; VERTIGO;

ADOLESCENT; ADULT; BLOOD PRESSURE; DOUBLE-BLIND METHOD; HALF-LIFE; HEADACHE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PYRIDINES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; TETRAZOLES; VASODILATOR AGENTS;

EID: 0036223958     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01158.x     Document Type: Article

References (25)

1. Long-lasting coronary vasoconstrictor effects and myocardial uptake of endothelin-1 in humans
2. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
3. Endothelin in renal pathophysiology: From experimental to therapeutic application
4. Endothelin-1 in heart failure. A new therapeutic target?
5. Endothelins and endothelin receptor antagonists. Therapeutic considerations for a novel class of cardiovascular drugs
6. Endothelin in human congestive heart failure
7. Endothelin-receptor antagonists. Current and future perspectives
8. Pharmacology of tezosentan, new endothelin receptor antagonist for parenteral use
9. Entry-into-man study with tezosentan, an intravenous dual endothelin receptor antagonist
10. Clearance of circulating endothelin-1 by ETB receptors in rats
11. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044
12. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects
13. Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: Effects on the regulation of renal vascular tone
14. Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans
15. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension
16. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade
17. Endothelin and ET (A) receptors in long-term arterial pressure homeostasis in conscious nonhuman primates
18. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure
19. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
20. Human endothelin-1 clearance kinetics revealed by a radiotracer technique
21. Endothelin in heart failure: A promising therapeutic target?
22. Recent discovery and development of endothelin receptor antagonists
23. New developments in heart failure: Role of endothelin and the use of endothelin receptor antagonists